0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

1
Letter to the Editor   |    
Dr. Rubin Replies
ROBERT T. RUBIN, M.D., Ph.D.
Am J Psychiatry 2004;161:1722-1722. doi:10.1176/appi.ajp.161.9.1722

To the Editor: I appreciate the opportunity to reply to several issues raised by Dr. Rothschild. First is my taking him to task for nondisclosure of a financial conflict of interest. When I wrote my review of Dr. Rothschild’s chapter, he had declared "a financial interest in Corcept Therapeutics" in a published article (1). Only recently did he clarify that "in the past, he has been a consultant to and received research grants from Corcept Therapeutics" (2). If Dr. Rothschild had provided a similar statement in the chapter in question, this issue would not have arisen.

Second is whether financial disclosures should be required in book chapters. I believe they should. Financial disclosure is a major issue now; e.g., following a recent exposé of the nondisclosure of several major financial conflicts in a review of depression treatments (3), the Nature Publishing Group extended its disclosure requirement to review articles (4). Other journals have expanded their disclosure policies to cover all published material, and public interest groups have lent their voice in support (5). Nevertheless, violations continue to surface; e.g., the controversy over nondisclosure in an article in the Lancet suggesting a link between measles-mumps-rubella vaccinations and pervasive developmental disorder in children (6). Even full disclosure, however, is not a panacea (7).

Third is the questionable efficacy of mifepristone in psychotic depression in contrast to Dr. Rothschild’s statement of its use in "rapidly reversing psychotic major depression." In the two published studies on this issue, there was no significant drug effect (1, 8). In the first study (8), two placebo cells were eliminated because they were considered a drug carryover effect, and an independent-samples analysis apparently was performed, even though the data were paired (subjects were their own control subjects). My independent, paired-data analysis yielded a clearly nonsignificant difference. In the second study, no statistical analysis at all was presented. My analysis of those outcome data again yielded a clearly nonsignificant difference. As well, the April 2004 initial public offering filed with the Securities and Exchange Commission by Corcept Therapeutics (9) indicates that even in large double-blind trials, only a small number of patients became asymptomatic, with no significant difference between drug and placebo. Does this medication, then, warrant the paean of "ECT in a bottle" (10)?

Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, Schatzberg AF: An open label trial of C-1073 (miferistone) for psychotic major depression. Biol Psychiatry  2002; 52:386–392
[PubMed]
[CrossRef]
 
Bell MA, Rothschild AJ: Psychotic depression. Curr Psychiatry  2004; 3:54–63
 
Carroll BJ, Rubin RT: Editorial policies on financial disclosure. Nat Neurosci  2003; 6:999–1000
[PubMed]
[CrossRef]
 
Financial disclosure for review authors (editorial). Nat Neurosci  2003; 6:997
[PubMed]
[CrossRef]
 
Jacobson MF, Sharpe VA: Editorial policies on financial disclosure. Nat Neurosci  2003; 6:1001
[PubMed]
[CrossRef]
 
Horton R: A statement by the editors of the Lancet. Lancet  2004; 363:820–821
[PubMed]
[CrossRef]
 
Horton R: The dawn of McScience. New York Review of Books, March 11, 2004
 
Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF: Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol  2001; 21:516–521
[PubMed]
[CrossRef]
 
Securities and Exchange Commission Form s-1 Registration Statement Under the Securities Act of 1933: Corcept Therapeutics Incorporated.
 
Gelenberg A: Mifepristone (RU486) for psychotic major depression. Biol Ther Psychiatry, Jan 2003
 
+

References

Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, Schatzberg AF: An open label trial of C-1073 (miferistone) for psychotic major depression. Biol Psychiatry  2002; 52:386–392
[PubMed]
[CrossRef]
 
Bell MA, Rothschild AJ: Psychotic depression. Curr Psychiatry  2004; 3:54–63
 
Carroll BJ, Rubin RT: Editorial policies on financial disclosure. Nat Neurosci  2003; 6:999–1000
[PubMed]
[CrossRef]
 
Financial disclosure for review authors (editorial). Nat Neurosci  2003; 6:997
[PubMed]
[CrossRef]
 
Jacobson MF, Sharpe VA: Editorial policies on financial disclosure. Nat Neurosci  2003; 6:1001
[PubMed]
[CrossRef]
 
Horton R: A statement by the editors of the Lancet. Lancet  2004; 363:820–821
[PubMed]
[CrossRef]
 
Horton R: The dawn of McScience. New York Review of Books, March 11, 2004
 
Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF: Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol  2001; 21:516–521
[PubMed]
[CrossRef]
 
Securities and Exchange Commission Form s-1 Registration Statement Under the Securities Act of 1933: Corcept Therapeutics Incorporated.
 
Gelenberg A: Mifepristone (RU486) for psychotic major depression. Biol Ther Psychiatry, Jan 2003
 
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Books
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 1.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 27.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 45.  >
APA Practice Guidelines > Chapter 0.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 9.  >
Topic Collections
Psychiatric News
APA Guidelines